Henlius and Intas receive positive CHMP opinion for HETRONIFLY® (approved in China as HANSIZHUANG) on European March
– HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for the first-line treatment of ES-SCLC – HETRONIFLY® (serplulimab) is expected to be the first anti-PD-1 monoclonal antibody…